AXIM 10-K Annual Report Dec. 31, 2021

AXIM BIOTECHNOLOGIES, INC.

10-Ks and 10-Qs

10-Q	Quarter ended June 30, 2024
10-Q	Quarter ended March 31, 2024
10-K	Fiscal year ended Dec. 31, 2023
10-Q	Quarter ended Sept. 30, 2023
10-Q	Quarter ended June 30, 2023
10-Q	Quarter ended March 31, 2023
10-K	Fiscal year ended Dec. 31, 2022
10-Q	Quarter ended Sept. 30, 2022
10-Q	Quarter ended June 30, 2022
10-Q	Quarter ended March 31, 2022
10-K	Fiscal year ended Dec. 31, 2021
10-Q	Quarter ended Sept. 30, 2021
10-Q	Quarter ended June 30, 2021
10-Q	Quarter ended March 31, 2021
10-K	Fiscal year ended Dec. 31, 2020
10-Q	Quarter ended Sept. 30, 2020
10-Q	Quarter ended June 30, 2020
10-Q	Quarter ended March 31, 2020
10-K	Fiscal year ended Dec. 31, 2019
10-Q	Quarter ended Sept. 30, 2019
10-Q	Quarter ended June 30, 2019
10-Q	Quarter ended March 31, 2019
10-K	Fiscal year ended Dec. 31, 2018
10-Q	Quarter ended Sept. 30, 2018
10-Q	Quarter ended June 30, 2018
10-Q	Quarter ended March 31, 2018
10-K	Fiscal year ended Dec. 31, 2017
10-Q	Quarter ended Sept. 30, 2017
10-Q	Quarter ended June 30, 2017
10-Q	Quarter ended March 31, 2017
10-K	Fiscal year ended Dec. 31, 2016
10-Q	Quarter ended Sept. 30, 2016
10-Q	Quarter ended June 30, 2016
10-Q	Quarter ended March 31, 2016
10-K	Fiscal year ended Dec. 31, 2015
10-Q	Quarter ended Sept. 30, 2015
10-Q	Quarter ended June 30, 2015
10-Q	Quarter ended March 31, 2015
10-K	Fiscal year ended Dec. 31, 2014
10-Q	Quarter ended Sept. 30, 2014
10-Q	Quarter ended June 30, 2014
10-Q	Quarter ended March 31, 2014
10-K	Fiscal year ended Dec. 31, 2013
10-Q	Quarter ended Sept. 30, 2013
10-Q	Quarter ended June 30, 2013
10-Q	Quarter ended March 31, 2013
10-K	Fiscal year ended Dec. 31, 2012
10-Q	Quarter ended Sept. 30, 2012
10-Q	Quarter ended June 30, 2012
10-Q	Quarter ended March 31, 2012
10-K	Fiscal year ended Dec. 31, 2011
10-Q	Quarter ended Sept. 30, 2011

Name: AXIM BIOTECHNOLOGIES, INC. CIK: 1514946 Filing Type: 10-K/A Report Date: 2021-12-31 Download URL: https://www.sec.gov/Archives/edgar/data/1514946/000109690622000902/axim_10k.htm

TABLE OF CONTENTS

Part I Item 1. Business Item 1A. Risk Factors Item 1B. Unresolved Staff Comments Item 2. Properties Item 3. Legal Proceedings Item 4. Mine Safety Disclosure Part II Item 5. Market For Registrant S Common Equity and Related Stockholder Matters and Issuer Purchases Of Equity Securities Item 6. [reserved]Item 7. Management S Discussion and Analysis Of Financial Condition and Results Of Operations Item 7A. Quantitative and Qualitative Disclosures About Market Risk Item 8. Financial Statement and Supplementary Data Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure Item 9A. Controls and Procedures Item 9B. Other Information Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections Part III Item 10. Directors, Executive Officers and Corporate Governance Item 11. Executive Compensation Item 12. Security Ownership Of Certain Beneficial Owners and Management and Related Stockholder Matters Item 13. Certain Relationships and Related Transactions, and Director Independence Item 14. Principal Accountant Fees and Services Item 15. Exhibits, Financial Statement Schedules Note 1: Organization Note 1: Organization (continued)Note 2: Acquisition Of Sapphire Biotech, Inc Note 2: Acquisition Of Sapphire Biotech, Inc. (continued)Note 3: Acquisition Of Intellectual Property Of Advanced Tear Diagnostic, Llc Note 4: Basis Of Presentation:Note 5: Going Concern Note 6: Significant Accounting Policies Note 6: Significant Accounting Policies (continued)Note 7: Prepaid Expenses Note 8: Promissory Note Note 8: Promissory Note (continued)Note 9: Other Commitments Note 9: Other Commitments (continued)Note 10: Related Party Transactions Note 11: Due To First Insurance Funding Note 12: Convertible Notes Payable Note 12: Convertible Notes Payable (continued)Note 13: Stock Incentive Plan Note 13: Stock Incentive Plan (continued)Note 14: Stockholders Deficit Note 14: Stockholders Deficit(continued)Note 14: Stockholders Deficit (continued)Note 15: Stock Options and Warrants Note 15: Stock Options and Warrants (continued)Note 16: Discontinued Operations Note 16: Discontinued Operations (continued)Note 17: Commitment and Contingencies Note 17: Commitment and Contingencies (continued)Note 18: Income Taxes Note 18: Income Taxes (continued)Note 19: Subsequent Events Note 19: Subsequent Events (continued)

Exhibits

Code of Business Conduct and Ethics. 14.1 10-Q 11/20/2017 Subsidiaries 21.1 Consent of Independent Registered Public Accounting Firm 23.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.1 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.1 Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2 Nominating and Governance Committee Charter. 99.1 10-Q 11/20/2017 Compensation Committee Charter. 99.2 10-Q 11/20/2017 Audit Committee Charter. 99.3 10-Q 11/20/2017

AXIM 10-K Fiscal year ended Dec. 31, 2021

Exhibits